Addex Therapeutics (ADDXF) Stock Price, News & Analysis

Company Overview

Addex Therapeutics Ltd. is a clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland. The company develops small-molecule medicines that target G protein-coupled receptors (GPCRs), a class of proteins involved in neurological and other biological processes. Its drug-discovery approach focuses on allosteric modulation, which is designed to influence receptor activity without directly competing with the receptor’s natural signaling molecules.

Addex’s research and development programs have included compounds targeting metabotropic glutamate receptors and the GABA-B receptor. Its lead programs have included ADX71149, a positive allosteric modulator of the mGlu2 receptor being investigated for neurological and psychiatric disorders, and ADX10061, an mGlu5 negative allosteric modulator studied for conditions including migraine. The company has also developed earlier-stage candidates and discovery programs based on its allosteric-modulator platform.

Founded in 2002, Addex has pursued collaborations and licensing relationships with larger pharmaceutical companies to advance selected drug candidates. The company serves the international pharmaceutical and biotechnology market from its Swiss base and is led by Chief Executive Officer Tim Dyer. Addex Therapeutics is listed on the SIX Swiss Exchange and its shares also trade over the counter in the United States under the symbol ADDXF.

Key Stats

• Today's Range: $0.99 to $0.99
• 50-Day Range: $0.99 to $0.99
• 52-Week Range: $0.99 to $0.99
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 9/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ADDXF
• CIK: N/A
• Web: www.addextherapeutics.com
• Phone: 41 22 884 1555
• Fax: N/A
• Employees: 26
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.25